Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

NCT00447057 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

Interventions

DRUG: Pemetrexed
DRUG: Erlotinib
DRUG: Pemetrexed
DRUG: Erlotinib

Sponsor

Eli Lilly and Company